Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
Myung‐Ju Ahn, Byoung Chul Cho, Xiaoling Ou, Andrew Walding, Angela W. Dymond, Song Ren, Mireille Cantarini, Pasi A. Jänne
Topics & Concepts
DurvalumabMedicineOsimertinibInternal medicinePneumonitisAdverse effectOncologyRamucirumabGastroenterologyNivolumabLungEpidermal growth factor receptorImmunotherapyCancerErlotinibLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisColorectal Cancer Treatments and Studies